Wednesday 29th July 2020
|Text too small?|
AFT Pharmaceuticals (NZX: AFT , ASX:AFT) today welcomes Medsafe’s announcement that all codeine and codeine-containing medicines will become prescription only from 5 November 2020.
Medsafe, which made the decision to reschedule all codeine and codeine-containing medicines last year, announced the timetable to give effect to the decision in a letter to the pharmaceutical industry released earlier this week.
The letter is attached to this release.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are pleased Medsafe has set a firm date for the rescheduling of codeine. We expect the move, which is aimed at reducing codeine overdoses and poisonings, will increase demand for alternative pain relief treatments including, AFT’s patented paracetamol and ibuprofen combination treatment Maxigesic.”
“In the 12 months after Australia rescheduled codeine containing medicines in 2018, sales of Maxigesic tablets increased by more than 50%. While it is unclear whether the New Zealand market will respond in a similar way, we expect the move to assist the growth of Maxigesic in New Zealand in the current financial year.”
Source: AFT Pharmaceuticals (NZX: AFT , ASX:AFT)
No comments yet
Heartland announces FY20 full year results
Geo Limited releases its FY20 Annual Report
Michael Hill International Limited announces 2020 annual report
Tower supports climate risk reporting
Tourism Holdings Limited Updated FY20 guidance
The Bankers Investment Trust Plc- Issue of Equity
Oio Consents to Acquisition of Metlifecare
Summerset Considers Retail Bond Offer
Z seeks previous corporate employees for remediation payment
SkyCity Announces Full Year Results